Cherkassy Regional Oncology Center

Cherkasy

0 studies enrolling now · 1 studies all time

What they study most

Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies

Studies at this site

• A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies — Running, not enrolling